Ozmosi | Molsidomine Drug Profile

Product Description

Mechanisms of Action: Nitric Oxide Transporter

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Therabel
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Muscle Weakness|Inflammation|Angina, Stable|Angina Pectoris|Atherosclerosis

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00382421	SWISSI 1	N/A	Completed	Coronary Artery Disease\|Myocardial Ischemia	None	2025-08-14	Primary Endpoints\|Treatments
2011-005534-19	2011-005534-19	P4	Completed	Inflammation\|Muscle Weakness	2024-12-02	2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT01363661	MEDCOR	P4	Completed	Angina, Stable\|Atherosclerosis\|Angina Pectoris	2014-09-01	2025-08-14	Primary Endpoints\|Treatments
2011-000190-31	MEDCOR2011	P4	Completed	Angina, Stable	2013-11-29	2022-03-13	Treatments

Recent News Events

Date	Type	Title
02/26/2024	PubMed	Anxiolytic-like Activity, Antioxidant Properties, and Facilitatory Effects on the Short-Term Memory Retention of Molsidomine in Rats.
11/01/2023	PubMed	Contribution of the gasotransmitter nitric oxide to the structural and functional organization of erythrocytes under conditions of hypoxia/reoxygenation.
09/28/2023	PubMed	The Nitric Oxide (NO) Donor Molsidomine Attenuates Memory Impairments Induced by the D1/D2 Dopaminergic Receptor Agonist Apomorphine in the Rat.
09/10/2023	News Article	The Molsidomine market includes a complete analysis of Molsidomine market size which is growing with a CAGR of 13.6% from 2023 to 2030.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Molsidomine

Alternative Names: molsidomine Clinical Status: Inactive Latest Update: 2024-02-26 Latest Update Note: PubMed Publication